Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07144293
PHASE2

Improving Physical Ability and Cellular Senescence Elimination in HIV

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

View on ClinicalTrials.gov

Summary

This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.

Key Details

Gender

All

Age Range

50 Years - Any

Study Type

INTERVENTIONAL

Enrollment

82

Start Date

2025-12-04

Completion Date

2026-11-29

Last Updated

2026-03-24

Healthy Volunteers

No

Interventions

DRUG

Dasatinib

Dasatinib will be administered as one 100 mg capsule.

DRUG

Quercetin

Quercetin will be administered as five 250 mg capsules.

OTHER

Placebo - Dasatinib

Matching Placebo for Dasatinib will be administered as one 100 mg capsule.

OTHER

Placebo - Quercetin

Matching Placebo for Quercetin will be administered as five 250 mg capsules.

Locations (27)

Alabama CRS (Site ID: 31788)

Birmingham, Alabama, United States

University of California, Los Angeles CARE Center CRS (Site ID: 601)

Los Angeles, California, United States

UCSD Antiviral Research Center CRS (Site ID: 701)

San Diego, California, United States

University of California, San Francisco HIV/AIDS CRS (Site ID: 801)

San Francisco, California, United States

Harbor University of California Los Angeles Center CRS (Site ID: 603)

Torrance, California, United States

University of Colorado Hospital CRS (Site ID: 6101)

Aurora, Colorado, United States

Whitman-Walker Institute, Inc. CRS (Site ID: 31791)

Washington D.C., District of Columbia, United States

The Ponce de Leon Center CRS (Site ID: 5802)

Atlanta, Georgia, United States

Northwestern University CRS (Site ID: 2701)

Chicago, Illinois, United States

Massachusetts General Hospital CRS (MGH CRS) (Site ID: 101)

Boston, Massachusetts, United States

Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS (Site ID: 107)

Boston, Massachusetts, United States

Washington University Therapeutics (WT) CRS (Site ID: 2101)

St Louis, Missouri, United States

New Jersey Medical School Clinical Research Center CRS (Site ID: 31786)

Newark, New Jersey, United States

Weill Cornell Chelsea CRS (Site ID: 7804)

New York, New York, United States

Columbia Physicians & Surgeons (P&S) CRS (Site ID: 30329)

New York, New York, United States

Weill Cornell Uptown CRS (Site ID: 7803)

New York, New York, United States

University of Rochester Adult HIV Therapeutic Strategies Network CRS (Site ID: 31787)

Rochester, New York, United States

Chapel Hill CRS (Site ID: 3201)

Chapel Hill, North Carolina, United States

Greensboro CRS (Site ID: 3203)

Greensboro, North Carolina, United States

Cincinnati CRS (Site ID: 2401)

Cincinnati, Ohio, United States

Case CRS (Site ID: 2501)

Cleveland, Ohio, United States

Ohio State University CRS (Site ID: 2301)

Columbus, Ohio, United States

Penn Therapeutics CRS (Site ID: 6201)

Philadelphia, Pennsylvania, United States

University of Pittsburgh CRS (Site ID: 1001)

Pittsburgh, Pennsylvania, United States

Vanderbilt Therapeutics (VT) CRS (Site ID: 3652)

Nashville, Tennessee, United States

Houston Advancing Research Team CRS (Site ID: 31473)

Houston, Texas, United States

University of Washington Positive Research CRS (Site ID: 1401)

Seattle, Washington, United States